TTI - TETRA Technologies, Inc.
Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) and B cells Company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal (GI) diseases - subject to additional funding Company to host investor webcast today, July 7 th , at 8:30am ET HOUSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced Phase 1 results for TTI-109, its next-generation STAT3 inhibitor. TTI-109 is a phosphate prodrug of TTI-101 designed to improve delivery and tolerability while preserving the parent compound's mechanism of action.
Tetra Technologies (TTI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Using Neptune Chemistry to Achieve Required Density With Lower Zinc Content; Awarded Three-Well 20k psi Deepwater Project in the Gulf of America With Estimated Start in 2026 SPRING, Texas, June 29, 2026 /PRNewswire/ -- TETRA Technologies, Inc. (NYSE: TTI) today announced the introduction of TETRA Neptune Z-Lite, a high-density completion fluid designed for deepwater and high-pressure well applications. The fluid system uses our patented Neptune fluid chemistry and expands the Company's completion fluids portfolio by offering up to 60% lower zinc-ion concentration than conventional zinc-based fluids while maintaining required density performance.
TETRA Technologies, Inc. (TTI) Presents at J.P. Morgan Natural Resources Conference 2026 Transcript
San Diego, California--(Newsfile Corp. - June 17, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation cysteamine-based therapies for rare diseases, including cystinosis and primary mitochondrial diseases, today announced the appointment of Gilad Aharon, PhD, to its Board of Directors. Dr. Aharon is a Co-Founder and Portfolio Manager at Rosalind Advisors, Inc., a Toronto-based life sciences institutional investor.
VIAV's new TETRA testing upgrade for the CX300 aims to speed deployments, cut costs, and reinforce its position in mission-critical radio testing.
Allows full testing of TETRA MS radios, including transmitter parametric measurements, call processing and BER/MER loopback without the need to place radios in T1 test mode CHANDLER, Ariz., June 15, 2026 /PRNewswire/ -- VIAVI Solutions Inc. (VIAVI) (NASDAQ: VIAV) has announced a TETRA MS radio base station simulator option for its field-portable CX300 communications service monitor.
Hallead acquired 22,000 shares on June 9, 2026, at a weighted average price of $9.86 per share, representing a transaction value of ~$217,000. This purchase increased his direct ownership by 14.79%, bringing his direct holdings to 170,764 shares after the transaction.
San Diego, California--(Newsfile Corp. - June 3, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, is pleased to announce that, further to its news releases of May 11 and June 1, 2026, it has completed an oversubscribed non-brokered private placement (the "Offering") through the issuance of 18,143,700 common shares (the "Offered Shares") at a price of C$0.50 per Offered Share for gross proceeds of C$9,071,850. All securities issued in connection with the Offering are subject to a four-month plus one day hold period ending October 2, 2026.
TETRA Technologies, Inc. Announces Pricing of Public Offering of Common Stock PR Newswire SPRING, Texas, June 2,
SPRING, Texas, June 2, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) today announced the pricing of an underwritten public offering of 10,810,811 shares of its common stock, par value $0.01 per share ("Common Stock"), at a price to the public of $9.25 per share, pursuant to an effective shelf registration statement on Form S-3 (the "Registration Statement") filed with the U.S. Securities and Exchange Commission (the "SEC"). The Company intends to use the net proceeds it receives from the offering for general corporate purposes, including funding a portion of the construction costs of its Arkansas bromine project.
SPRING, Texas, June 2, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) today announced the commencement of an underwritten public offering of $100 million of shares of its common stock, par value $0.01 per share ("Common Stock"), pursuant to an effective shelf registration statement on Form S-3 (the "Registration Statement") filed with the U.S. Securities and Exchange Commission (the "SEC"). The Company intends to use the net proceeds it receives from the offering for general corporate purposes, including funding a portion of the construction costs of its Arkansas bromine project.
San Diego, California--(Newsfile Corp. - June 1, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, today announced that, due to strong investor demand, it has increased the size of its previously announced non-brokered private placement (the "Offering") (see the Company's news release dated May 11, 2026) from 16 million to approximately 18 million common shares at a price of $0.50 per Common Share of the Company for gross proceeds of approximately $9 million. The Offering has received conditional acceptance from the TSX Venture Exchange.
Strong Project Economics and Growth Outlook With a Secure U.S. Bromine Supply SPRING, Texas, May 28, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) today announced that its Board of Directors has conditionally approved the final investment decision ("FID") for the development of the Company's bromine production facility near Stamps, Arkansas (the "Evergreen Project"). The Board's authorization is subject to the Company finalizing financing for the Evergreen Project.
San Diego, California--(Newsfile Corp. - May 11, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, announced today that it will undertake a non-brokered private placement (the "Offering") of up to 16,000,000 common shares of the Company ("Offered Shares") at a price of $0.50 per Common Share for gross proceeds of $8 million. This Offering is subject to the approval of the TSX Venture Exchange (the "Exchange").
TETRA Technologies reported decade-high Q1 2026 revenue and EBITDA, with EPS coming 100% above estimates despite flat year-over-year growth. The company is constructing an Arkansas bromine facility for zinc bromide electrolyte battery supply. This is the project that contributes to the growth of the company in the near future. At 14x EV/EBITDA, TTI trades at the same multiple as Generac, although TTI holds bromine supply chain exposure and dominant deepwater completion fluid market share.
Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) on track for 2H 2026 Cash runway expected to be sufficient to fund operations through clinical readouts and into Q4 2026 HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the first quarter ended March 31, 2026, and provided a business update. Recent Progress and Upcoming Catalysts: TTI-109 (Healthy Volunteer Study): Study ongoing with topline data anticipated in June 2026.
TETRA Technologies, Inc. (TTI) Q1 2026 Earnings Call Transcript
Tetra Technologies (TTI) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.11 per share a year ago.